Abstract
Osteoarthritis is (OA) is a chronic slowly progressive inflammatory disease, in the pathogenesis of which a large role is assigned to immune disorders: increased synthesis of proinflammatory cytokines (interleukin 1, tumor necrosis factor-α) that activate catabolic processes not only in cartilaginous tissue, but also in subchondral bone and other joint structures. Nonsteroidal anti-inflammatory drugs are recommended to be used as symptom-modifying agents that block the production of prostaglandins. The choice of slowly symptomatic drugs is rather wide. Diacerein is one of them. The author has evaluated the efficacy and safety of diacerein in the treatment of knee and hip OA over a period of 7 years. She also presents her own experience in using the drug.
Highlights
Use of diacerein for the treatment of large joint osteoarthritis (A review of literature and the author’s own experience) Balabanova R.M
Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115552; Osteoarthritis is (OA) is a chronic slowly progressive inflammatory disease, in the pathogenesis of which a large role is assigned to immune disorders: increased synthesis of proinflammatory cytokines that activate catabolic processes in cartilaginous tissue, and in subchondral bone and other joint structures
Nonsteroidal anti-inflammatory drugs are recommended to be used as symptom-modifying agents that block the production of prostaglandins
Summary
Use of diacerein for the treatment of large joint osteoarthritis (A review of literature and the author’s own experience) Balabanova R.M. В хондроцитах эти цитокины активируют синтез протеаз, особенно металлопротеиназ (ММП), а также снижают синтез коллагена II и IХ типов, протеогликанов, тканевого ингибитора ММП, стимулируют выработку кислородных радикалов, оксида азота, что способствует прогрессированию катаболических процессов в хряще. Первоочередной целью лечения ОА является уменьшение или купирование боли, что приводит к улучшению функции сустава и качества жизни пациента. При выборе НПВП у пожилых больных необходимо учитывать особенности его фармакодинамики, совместимость с препаратами, используемыми для лечения сопутствующих заболеваний, безопасность в плане возникновения нежелательных реакций (НР), а также влияние на хрящ [4, 5].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call